Results 41 to 50 of about 815 (103)

Gossypol Broadly Inhibits Coronaviruses by Targeting RNA‐Dependent RNA Polymerases

Advanced Science, Volume 9, Issue 35, December 19, 2022., 2022
Gossypol is identified as an effective inhibitor against SARS‐CoV‐2 RNA‐dependent RNA polymerases. It exhibits excellent antiviral activity against SARS‐CoV‐2 and its variants of concern as well as all examined viruses from the four main phylogenetic branches of coronaviruses, which makes gossypol a novel broad‐spectrum anti‐coronavirus inhibitor that ...
Wenjing Wang, Wenkang Li, Zhiyuan Wen, Chong Wang, Weilong Liu, Yufang Zhang, Juncheng Liu, Tianze Ding, Lei Shuai, Gongxun Zhong, Zhigao Bu, Lingbo Qu, Maozhi Ren, Fuguang Li   +13 more
wiley   +1 more source

Molnupiravir: A new candidate for COVID‐19 treatment

Pharmacology Research & Perspectives, 2022
The novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID‐19.
Fariba Pourkarim, Samira Pourtaghi‐Anvarian, Haleh Rezaee   +2 more
doaj   +1 more source

AVANÇOS RECENTES NA SÍNTESE DO REMDESIVIR, MOLNUPIRAVIR (EIDD-2801) E TENOFOVIR: MOLÉCULAS PROMISSORAS NO TRATAMENTO DA COVID-19

Química Nova, 2021
RECENT ADVANCES IN THE SYNTHESIS OF REMDESIVIR, MOLNUPIRAVIR (EIDD-2801) AND TENOFOVIR: PROMISING MOLECULES IN THE TREATMENT OF COVID-19. The search for new treatments to contain the Covid-19 pandemic has highlighted the importance of nucleoside antivirals, such as Remdesivir, Tenofovir and Molnupiravir.
Taniris Braga, Juliana dos Santos, Pedro de Castro, Giovanni Amarante   +3 more
openaire   +3 more sources

Safety and efficacy of molnupiravir in SARS‐CoV‐2‐infected patients: A real‐life experience

Journal of Medical Virology, Volume 94, Issue 11, Page 5582-5588, November 2022., 2022
Abstract Since the start of the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) pandemic, several treatments have been proposed to cure coronavirus disease 2019 (COVID‐19) and prevent it. Molnupiravir is a ribonucleoside prodrug of N‐hydroxycytidine with an in vitro and in vivo activity against SARS‐CoV‐2.
Andrea De Vito, Agnese Colpani, Alessandra Bitti, Beatrice Zauli, Maria Chiara Meloni, Marco Fois, Lucia Denti, Sara Bacciu, Claudia Marcia, Ivana Maida, Sergio Babudieri, Giordano Madeddu   +11 more
wiley   +1 more source

Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections

Viruses, 2021
Background: There is an urgent need for new antivirals with powerful therapeutic potential and tolerable side effects. Methods: Here, we tested the antiviral properties of interferons (IFNs), alone and with other drugs in vitro. Results: While IFNs alone
Aleksandr Ianevski, Rouan Yao, Eva Zusinaite, Laura Sandra Lello, Sainan Wang, Eunji Jo, Jaewon Yang, Erlend Ravlo, Wei Wang, Hilde Lysvand, Kirsti Løseth, Valentyn Oksenych, Tanel Tenson, Marc P. Windisch, Minna M. Poranen, Anni I. Nieminen, Svein Arne Nordbø, Mona Høysæter Fenstad, Gunnveig Grødeland, Pål Aukrust, Marius Trøseid, Anu Kantele, Eglė Lastauskienė, Astra Vitkauskienė, Nicolas Legrand, Andres Merits, Magnar Bjørås, Denis E. Kainov   +27 more
doaj   +1 more source

Comparative docking and molecular dynamics studies of molnupiravir (EIDD-2801): implications for novel mechanisms of action on influenza and SARS-CoV-2 protein targets

Journal of Biomolecular Structure and Dynamics, 2023
Molnupiravir (EIDD-2801) (MLN) is an oral antiviral drug for COVID-19 treatment, being integrated into viral RNA through RNA-dependent RNA polymerase (RdRp). Upon ingestion, MLN is transformed into two active metabolites: β-d-N4-hydroxycytidine (NHC) (EIDD-1931) in the host plasma, and EIDD-1931-triphosphate (MTP) within the host cells. However, recent
Şıhoğlu, Arzuhan, İstifli, Erman Salif, Okumuş, Nurullah, Sarıkürkcü, Cengiz, Kuhn, Eduardo Ramires, Netz, Paulo Augusto   +5 more
openaire   +2 more sources

Enzyme‐mediated synthesis of Molnupiravir: paving the way for the application of biocatalysis in pharmaceutical industry

ChemCatChem, Volume 14, Issue 13, July 7, 2022., 2022
Nowadays, the use of enzyme‐mediated processes in the industry for API manufacturing is gaining ground concerning traditional chemical methods. This Concept article addresses recent enzymatic and chemo‐enzymatic strategies for the synthesis of the anti‐COVID‐19 agent Molnupiravir Abstract Molnupiravir (Lagevrio®) is an orally‐administered anti‐COVID‐19
Guillermo Cruz, Javier Acosta, Jon Del Arco, Vicente Javier Clemente‐Suarez, Víctor Deroncele, Jesús Fernández‐Lucas   +5 more
wiley   +1 more source

Identification and Tracking of Antiviral Drug Combinations

Viruses, 2020
Combination therapies have become a standard for the treatment for HIV and hepatitis C virus (HCV) infections. They are advantageous over monotherapies due to better efficacy, reduced toxicity, as well as the ability to prevent the development of ...
Aleksandr Ianevski, Rouan Yao, Svetlana Biza, Eva Zusinaite, Andres Mannik, Gaily Kivi, Anu Planken, Kristiina Kurg, Eva-Maria Tombak, Mart Ustav, Nastassia Shtaida, Evgeny Kulesskiy, Eunji Jo, Jaewon Yang, Hilde Lysvand, Kirsti Løseth, Valentyn Oksenych, Per Arne Aas, Tanel Tenson, Astra Vitkauskienė, Marc P. Windisch, Mona Høysæter Fenstad, Svein Arne Nordbø, Mart Ustav, Magnar Bjørås, Denis E. Kainov   +25 more
doaj   +1 more source

AI-guided discovery of the invariant host response to viral pandemics

EBioMedicine, 2021
Background: Coronavirus Disease 2019 (Covid-19) continues to challenge the limits of our knowledge and our healthcare system. Here we sought to define the host immune response, a.k.a, the “cytokine storm” that has been implicated in fatal COVID-19 using ...
Debashis Sahoo, Gajanan D. Katkar, Soni Khandelwal, Mahdi Behroozikhah, Amanraj Claire, Vanessa Castillo, Courtney Tindle, MacKenzie Fuller, Sahar Taheri, Thomas F. Rogers, Nathan Beutler, Sydney I. Ramirez, Stephen A. Rawlings, Victor Pretorius, Davey M. Smith, Dennis R. Burton, Laura E. Crotty Alexander, Jason Duran, Shane Crotty, Jennifer M. Dan, Soumita Das, Pradipta Ghosh   +21 more
doaj   +1 more source

DFT study of Anti Sars-Cov-2 EIDD-1931 and EIDD-2801 molecular structures

Anais do VIII Simpósio de Estrutura Eletrônica e Dinâmica Molecular, 2020
Scientists around the world are joining efforts in the study of the current SARS-CoV-2 virus and the Covid-19 disease. As a result, several compounds have been studied for the treatment of SARS-CoV-2, among them there are N4-hydroxycytidine prodrug (NHC; EIDD-1931), and EIDD-2801, that have shown antiviral activity against SARS-CoV-2.
Antonio L. de Almeida, João B. L. Martins   +1 more
openaire   +1 more source